News

In 2026, the Pharmaceutical and Medical Device sectors face a "split-tier" EPR reality. Unlike general consumer goods, pharma has specific exemptions and unique traps that redefine how you handle your regulatory infrastructure for this niche. By leveraging the insights...

Novo Nordisk and Vivtex have formalised a collaboration aimed at advancing next-generation oral biologic therapies targeting obesity, diabetes and related comorbidities. Under the terms of the agreement, Vivtex will grant Novo Nordisk licences to selected oral drug-delivery technologies. In return,...

Addiction recovery has evolved into a multidisciplinary clinical domain where pharmacological interventions and holistic modalities increasingly coexist within structured treatment frameworks. As clinical evidence continues to validate both biochemical and behavioral pathways of recovery, treatment providers are adopting integrative...

Eli Lilly said that its weight-loss medicine Zepbound, when used in combination with psoriasis treatment Taltz, delivered stronger outcomes than Taltz alone in patients living with both psoriasis and obesity in a late-stage study. The psoriasis trial enrolled 274 patients...

Johnson & Johnson announced that it plans to invest more than $1 billion to construct a new cell therapy facility in Pennsylvania. The move forms part of the company’s broader strategy, unveiled last year, to expand its U.S. manufacturing...

Biopharmaceutical innovation increasingly depends on understanding biology at the cellular level. As therapies become more targeted and personalized, researchers must analyze how individual cells respond to treatment, interact with their environment, and signal changes within complex systems. Precision cellular...

Johnson & Johnson (J&J) has obtained approval from the US Food and Drug Administration (FDA) for a revised dosing schedule of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), introducing a once-monthly administration option for patients with advanced, epidermal growth factor receptor...